



Disentangling craving- and valence-related brain responses to smoking cues in individuals with nicotine use disorder

Amelie Haugg^{1,2}  | Andrei Manoliu^{1,3,4} | Ronald Sladky² | Lea M. Hulka¹ |
Matthias Kirschner^{1,5} | Annette B. Brühl¹ | Erich Seifritz¹ | Boris B. Quednow¹  |
Marcus Herdener¹ | Frank Scharnowski^{1,2}

¹Psychiatric University Hospital Zurich, Zurich, Switzerland

²Faculty of Psychology, University of Vienna, Vienna, Austria

³McLean Hospital, Belmont, Massachusetts, USA

⁴Harvard Medical School, Harvard University, Boston, Massachusetts, USA

⁵Montreal Neurological Institute, McGill University, Montreal, Canada

Correspondence

Amelie Haugg, Psychiatric University Hospital Zurich, Lenggstrasse 31, Zurich 8032, Switzerland.

Email: amelie.haugg@uzh.ch

Funding information

National Bank Fellowship Award; Baugarten Stiftung; Foundation for Research in Science and the Humanities at the University of Zurich, Grant/Award Number: STWF-17-012; Swiss National Science Foundation, Grant/Award Numbers: 100014_178841, 32003B_166566, BSSG10_155915, P2SKP3_178107; Forschungskredit of the University of Zurich, Grant/Award Number: FK-18-030

Abstract

Tobacco smoking is one of the leading causes of preventable death and disease worldwide. Most smokers want to quit, but relapse rates are high. To improve current smoking cessation treatments, a better understanding of the underlying mechanisms of nicotine dependence and related craving behaviour is needed. Studies on cue-driven cigarette craving have been a particularly useful tool for investigating the neural mechanisms of drug craving. Here, functional neuroimaging studies in humans have identified a core network of craving-related brain responses to smoking cues that comprises of amygdala, anterior cingulate cortex, orbitofrontal cortex, posterior cingulate cortex and ventral striatum. However, most functional Magnetic Resonance Imaging (fMRI) cue-reactivity studies do not adjust their stimuli for emotional valence, a factor assumed to confound craving-related brain responses to smoking cues. Here, we investigated the influence of emotional valence on key addiction brain areas by disentangling craving- and valence-related brain responses with parametric modulators in 32 smokers. For one of the suggested key regions for addiction, the amygdala, we observed significantly stronger brain responses to the valence aspect of the presented images than to the craving aspect. Our results emphasize the need for carefully selecting stimulus material for cue-reactivity paradigms, in particular with respect to emotional valence. Further, they can help designing future research on teasing apart the diverse psychological dimensions that comprise nicotine dependence and, therefore, can lead to a more precise mapping of craving-associated brain areas, an important step towards more tailored smoking cessation treatments.

KEYWORDS

craving, cue-reactivity, functional Magnetic Resonance Imaging, neuroimaging, nicotine use disorder, smoking

Amelie Haugg and Andrei Manoliu contributed equally to this work.

[Correction added on 7 April 2022, after first online publication: CSAL funding statement has been added.]

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2021 The Authors. *Addiction Biology* published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction.

1 | INTRODUCTION

Tobacco smoking is one of the leading risk factors for preventable death and disease worldwide, and it is estimated to kill 8 million users per year.^{1,2} Even though the number of nicotine-dependent smokers who want to quit smoking is large,³ many smokers are not successful with their smoking cessation goals, and relapse rates are high.⁴ In addition, the efficacy of available psychological and pharmacological treatments against nicotine dependence is still limited.⁵ Causes for smoking relapse are diverse, and, to date, a wide range of factors that have an effect on relapse rates have been identified, such as perceived stress,⁶ impulsivity,⁷ or low self-efficacy.⁸

Another important factor that influences success in quitting to smoke is the individual's smoking-related craving⁹ and the ability to control this craving.^{10,11} Craving, or, more precisely, drug craving, is commonly described as the 'desire to use a drug',¹² even though precise operational definitions can still vary largely across studies.¹³ In particular, Shiffman and colleagues¹⁴ observed cigarette craving after waking up to be predictive for smoking relapse in smokers who wanted to quit. Consequently, encountering social situations associated with smoking and other craving-inducing environments pose serious problems for smokers to reach their goal of sustained abstinence. Therefore, cigarette craving has been intensively studied with different methods.¹³ For example, self-report questionnaires, which can vary from a single visual analogue scale¹⁵ to more complex, multi-dimensional questionnaires such as the Questionnaire on Smoking Urges,²⁹ have been established as suitable methods to assess baseline craving levels. Another important approach that focuses more on situationally induced craving is the so-called cue-reactivity paradigm.^{16,17} Here, smokers are exposed to smoking cues, such as real cigarettes or visual stimuli that depict smoking scenes, and their subjective, behavioural or physiological craving response is measured. Cue-reactivity paradigms combined with neuroimaging are particularly suitable for identifying human brain responses associated with craving.¹⁸⁻²⁰

Recent meta-analyses of cue-reactivity functional Magnetic Resonance Imaging (fMRI) studies found relatively robust drug cue-related brain activity in the ventral striatum, amygdala, anterior cingulate cortex (ACC), posterior cingulate cortex (PCC) and orbitofrontal cortex (OFC)¹⁸⁻²⁰ (see Figure 1). These brain areas were repeatedly identified in cue-reactivity studies and may play an important role in the neural mechanisms underlying substance use disorders.³⁰ For instance, the ventral striatum is considered as one of the most prominent reward-associated areas and has been directly linked to reward processing and reward learning in animal and human studies,²¹ making it a key area involved in addiction. Also, the amygdala, next to its strong involvement in emotional processes,²² also mediates Pavlovian processing, making it a crucial instance in the learning of associations between environmental cues and drug-induced reward and, therefore, in reinforcing drug seeking behaviour.²³ The ACC, PCC and OFC, known to be involved in higher order cognitive processes, have also been linked to neural mechanisms related to substance use disorder: the ACC as a particularly strongly connected brain area is associated with decision-making as well as executive control and exerts top-




FIGURE 1 Most commonly observed brain areas in fMRI-based cue-reactivity studies. Cue-reactivity meta-analyses¹⁸⁻²⁰ identified a wide range of different brain areas driven by drug cues, with the amygdala (Amy), the ventral striatum (VS), the anterior cingulate cortex (ACC), the orbitofrontal cortex (OFC) and the posterior cingulate cortex being the most robustly identified cue-driven brain areas

down control over reward-related areas such as the ventral striatum.²⁴ The OFC is involved in evaluating the value of rewards and, therefore, another important area for reward processing.²⁵ Finally, the PCC has been observed to be more indirectly involved in substance use disorder. The PCC is part of the default mode network and associated with self-related processes, being activated when resisting cue-driven craving.²⁶

Cue-reactive brain responses have also been shown to be predictive of smoking abstinence and relapse,^{27,28} thus further underlining the clinical importance of understanding the neural mechanisms in these brain areas regarding nicotine dependence and craving.

The multifaceted neural underpinnings of smoking cue-reactivity reflect the many psychological dimensions that are associated with the perception and processing of such cues. Smoking cues are associated with the urge to smoke as well as factors such as the positive or negative connotation of the depicted situation. Consequently, the unique contribution of smoking-related craving to measured neural responses can be confounded by other stimulus dimensions that, as well, influence addiction-related brain areas. In particular, the emotional dimension of smoking cues can potentially confound craving-associated responses, as affective stimuli have been shown to strongly engage brain areas like the amygdala,³¹ an area that has also been identified in a wide range of cue-reactivity studies.¹⁸⁻²⁰ This is of particular relevance as the majority of fMRI-based cue-reactivity studies (e.g., 80% of the fMRI studies analysed in the aforementioned three meta-analyses) used a classical fMRI block design to identify brain areas that are related to smoking-associated cues: blocks of drug-related images are presented in an alternating fashion with blocks of neutral images. An fMRI block design provides considerably large statistical power to detect effects, but its inflexible design of a priori selected images for each stimulus block does not allow for further

analyses with respect to other stimulus characteristics.³² This inflexibility can, consequently, be problematic when other stimulus characteristics (other than the ones chosen for designing the stimulus blocks) are driving different/additional brain dynamics. For instance, craving-related brain regions might also be related to other aspects of the presented smoking cues, such as their emotional content.

To overcome this limitation, we applied an event-related parametric fMRI design combined with ratings of craving and valence as behavioural measures to disentangle core components of craving- and valence-related brain regions. This allowed us to identify key regions within the 'addiction network'³⁰ that were more sensitive to and more driven by either the craving or the emotional content of the presented craving cues. A better understanding of specific craving—as well as valence-related brain activations—can help to optimize future cue-reactivity paradigms and, more importantly, can help to identify more reliable targets for clinical interventions, such as cue-exposure therapy or real-time fMRI neurofeedback.

2 | MATERIAL AND METHODS

2.1 | Participants

Thirty-two subjects with nicotine use disorder (age: 25.93 ± 5.30 ; 16 females, 15 males and 1 non-binary; average daily cigarette consumption of 11.47 ± 5.57 cigarettes; smoking duration of 7.41 ± 4.76 years) participated in the study. This sample size is based on power calculations using previous studies included in cue-reactivity meta-analyses^{18–20} with maximally 31 subjects that have been able to reject the null hypothesis in one or more voxels (α -error probability of 5% adjusted for multiple comparisons). All subjects gave informed written consent and were compensated for their participation in the study (25CHF/h). Exclusion criteria were mental or neurological disorders, MRI-incompatibility criteria (i.e., metal implants, current pregnancy and pacemakers), as well as the use of any non-cigarette tobacco substitutes, such as nicotine patches, chewing gums or electronic cigarettes. Inclusion criterion was tobacco use disorder according to DSM-5.

2.2 | Experimental procedure and design

All subjects were instructed to abstain from smoking at least 1 h before the study. Prior to scanning, subjects were asked to fill out several questionnaires which included a drug use anamnesis of current and past drug use (previously described in Quednow et al.³³), the Fagerström Test for Nicotine Dependence³⁴ and the brief Questionnaire of Smoking Urges (QSU).³⁵ The QSU was filled out a second time in the end of the experimental session.

In the MRI session, subjects underwent a passive viewing paradigm (code for image presentation available at <https://osf.io/6y8fu/>) where they were presented a total of 330 neutral and nicotine-related images, distributed over five runs of 4 min each (see Figure 2). During

each run, 68 images were presented for 2.3 s in random order, each followed by a 1-s fixation dot as baseline. In the beginning of each run, a 15-s fixation dot baseline was presented. To ensure that all images were passively viewed by the subjects and subjects were paying attention to the images, 10 additional catch trial images were randomly presented during the five runs.

Participants were instructed to perform a button press when a catch trial image, depicting an exclamation mark, was presented. All images were taken from the Smoking Cue Database (SmoCuDa),³⁶ the International Affective Picture System (IAPS) database,³⁷ and the International Smoking Image Series (ISIS) database³⁸ and covered a continuous range from very mild to very intense craving-inducing content. To control for habituation effects, all images were presented only once and in randomized order in the MR scanner. Before and after the passive viewing runs, participants also performed 7-min resting state scans where they had to fixate a white fixation dot over a black background. After the functional imaging, we acquired an anatomical image. In total, one scanning session took approximately 50 min.

After scanning, subjects were asked to rate the 330 images that were presented during the passive viewing paradigm on a 100-point visual analogue scale outside the scanner. All images were presented in random order and had to be rated on two dimensions: the subject's urge to smoke when seeing the image (craving) and how positively or negatively the subject perceived the image (valence). A detailed description of the rating procedure can be found in Manoliu et al.³⁶

2.3 | MRI data acquisition

MR images were acquired with a 3 Tesla Philips Achieva scanner (Philips Healthcare, the Netherlands) using a 32-channel head coil at the MR Center of the Psychiatric University Hospital in Zurich, Switzerland. Functional images during the passive viewing paradigm were acquired using a T2*-weighted gradient-echo planar imaging (EPI) sequence with repetition time (RT) = 2,000 ms, echo time (TE) = 35 ms, flip angle (FA) = 82°, 27 slices in ascending order, interslice gap = 1 mm, voxel size = $2 \times 2 \times 3$ mm³ and field of view (FoV) = $220 \times 220 \times 109$ mm³. Five dummy scans as well as 122 functional images were collected during each 4-min passive viewing run. Further, a T1-weighted sequence in the end of the session was acquired with FA = 8°, 237 sagittal slices in ascending order, no slice gap, voxel size = $0.76 \times 0.76 \times 0.76$ and FoV = $255 \times 255 \times 180$ mm³. The anatomical run took 8:26 min.

2.4 | fMRI analysis

All functional MR images were analysed using MATLAB2017a and Statistical Parametric Mapping (SPM12; Wellcome Trust Centre for Neuroimaging, London, United Kingdom). Preprocessing of the functional images included slice-time correction, realignment, co-registration of the functional scans to the anatomical image,




FIGURE 2 Experimental design. The study was divided into three parts. In the first part, subjects filled out several questionnaires on their smoking routines. Then, subjects underwent 50 min of scanning, including resting state scans, five runs of passive viewing and an anatomical scan. During each passive viewing run, 68 out of a total of 340 neutral or nicotine-related images (including 10 additional catch trial images) were presented for 2.3 s in random order, followed by a 1-s fixation dot baseline. Finally, subjects rated all 330 presented images with respect to craving and valence

segmentation, normalization into Montreal Neurological Institute (MNI) space and smoothing with a Gaussian kernel of 6 mm full width at half maximum.

Before the parametric analysis, we applied a more standard cue-reactivity analysis without parametric modulation to replicate previous approaches. For this, we first specified a general linear model (GLM) with three regressors for high and low craving-intensity smoking stimuli as well as neutral stimuli and included the six motion parameters as well as the catch trials as regressors of no interest. We then contrasted smoking images that were rated as highly craving inducing, defined as images that received a craving rating of 50 or higher, with neutral images (high-craving-vs.-neutral contrast). Overall, 60 stimuli were defined as neutral, 129 stimuli were defined as high-craving and 141 stimuli were defined as low-craving stimuli, based on mean group ratings.

For our parametric analyses, we specified two GLMs, GLM-craving and GLM-valence. Each GLM contained the six motion parameters as regressors of no interest and one regressor representing the presented images. GLM craving additionally contained one parametric modulator for the craving rating for each presented stimulus, while GLM valence additionally contained one parametric modulator for the valence rating for each presented stimulus. In both GLMs, catch trials

were modelled as an additional regressor of no interest. Contrast images representing the craving and valence regressor, respectively, were used for second level analyses.

For the region of interest (ROI)-based analysis, we extracted average values from the beta images of the craving and valence parametric regressor of the first level analyses, for each ROI, using custom MATLAB scripts (all used scripts can be found on the Open Science Framework: <https://osf.io/6y8fu/>). The ROIs were defined based on fMRI cue-reactivity meta studies¹⁸⁻²⁰ and included the ventral striatum, amygdala, orbitofrontal cortex, anterior cingulate cortex and posterior cingulate cortex (see the supporting information for a detailed description of ROI selection and definition and the Open Science Framework repository for the mask files: <https://osf.io/6y8fu/>). One meta-analysis did not differentiate between cue-reactivity studies on different substance use disorders¹⁸; for the other two meta-analyses, we focused on results based on smoking cue-reactivity only. We compared the extracted craving- and valence-beta values using paired *t* tests. To investigate brain-behaviour relationships, we performed Spearman correlation analyses between extracted beta values and Fagerström dependence scores as well as the number of daily smoked cigarettes, respectively.

2.5 | Behavioral analysis

Ratings of the parametric modulators were based on average ratings across 40 nicotine-dependent subjects, including the 32 participants of this study, and were performed after the scanning session. A detailed description of the rating procedure and rating distributions has been published in Manoliu et al.³⁶

2.6 | Statistical analyses

All statistical cluster-level analyses of fMRI data were performed using an initial cluster defining threshold of $p < 0.001$ and family-wise-error (FWE) corrections of 0.05. Paired t tests between craving and valence betas were corrected for multiple comparisons using Bonferroni corrections.

2.7 | Code and data availability

The used smoking stimuli, a more detailed overview of stimuli ratings and the exact scripts used for performing stimulus ratings are all available on the Open Science Framework (OSF) platform (<https://osf.io/6gwy5/>). Further, we have made all scripts used for fMRI analyses, and image presentation is publicly available in another repository on the OSF platform (<https://osf.io/6y8fu/>). This repository also includes

group-level neuroimaging data, while individual data were not allowed to be shared publicly by our local ethics regulations.

3 | RESULTS

3.1 | Brain response to high-craving smoking images as compared to neutral images

To replicate conventional cue-reactivity analyses, we contrasted high-craving-versus-neutral, depicting brain areas related to high-in-craving-rated smoking images as compared to neutral images. Our analysis revealed significant (0.05 FWE-corrected) activation in the higher order visual cortices, the medial prefrontal cortex and ACC, and the PCC (see Figure 3 and Table S1 for details). For completeness, we report the respective results for a low-craving-versus-neutral contrast in the supporting information (Figure S1 and Table S2). Finally, we found significant small-volume corrected activation for the ACC, OFC and PCC, but not the amygdala and ventral striatum (Table S6).

3.2 | Disentangling craving and valence activations

To disentangle brain activations associated specifically with craving or valence, we parametrically analysed responses to the craving and valence rating, respectively. Whole brain analyses revealed significant




FIGURE 3 Whole-brain analysis results depicting brain areas activated by high-craving smoking images as contrasted to neutral images. The high-craving-versus-neutral contrast revealed activation in the higher order visual cortices, the prefrontal cortex (PFC) and anterior cingulate cortex (ACC) and the posterior cingulate cortex (PCC)

craving-related activation within the visual cortex, the PFC and ACC, the PCC, the parietal cortex, the fusiform gyrus and the precuneus, while significant valence-related activation was observed for the visual cortex and the parietal cortex. More details can be found in the supporting information (Figures S2 and S3; Tables S3 and S4).

In a second step, we specifically investigated craving- and valence-associated activity within our five predefined ROIs, namely ACC, amygdala, OFC, PCC and ventral striatum. The craving regressor showed significant small volume-corrected activation in the OFC, the ACC, the ventral striatum and the PCC (Figure 4; Table S5). In contrast, the valence regressor only showed significant small volume-corrected activation within the amygdala. Statistical comparisons using paired *t* tests showed a significant difference between the craving- and valence-related responses in the amygdala, with valence-related amygdala activity being significantly higher than craving-related activity ($t[31] = 4.41, p < 0.001$; Figure 4). The other four investigated ROIs did not show significant differences between craving- and valence-related brain responses. Nevertheless, in these four ROIs, craving-related brain responses were higher than valence-related brain responses with the latter often reaching values close to zero (see Figure 4). Further details can be found in Table S5.

4 | DISCUSSION

Nicotine use disorder is functionally multidimensional, and so is the neural response to smoking-related cues. Here, we disentangled brain responses to two core dimensions associated with smoking-related

cues: craving and valence. Using a parametric fMRI design, we investigated the influence of craving and valence aspects on key addiction brain areas: the amygdala, the ventral striatum, the ACC, the PCC and the OFC. Our approach enables a more precise mapping of craving-associated brain areas.

Our results show that the chosen brain areas that are robustly recruited by smoking cues in meta-analyses^{18–20} were indeed activated by the craving-aspect of the presented cues (Figure 4). Here, it should be noted that smoking cue reactivity in single studies can be dependent on context (e.g., drug availability right after the scanning session) and the subject population (e.g., treatment seeking subjects vs. non-treatment seeking subjects) and, therefore, might differ from large-scale meta-analyses.³⁹

However, when isolating the emotional content of the smoking cues and its influence on neural responses within these ROIs, we observed that amygdala activation is related to the images' valence ratings. This valence-related response in the amygdala was significantly stronger than the craving-related amygdala response. In contrast, the ACC, ventral striatum, OFC and PCC were not (strongly) affected by the emotional content of the presented images. Hence, the amygdala responds primarily to the valence dimension of smoking cues, which is a novel finding in the cue-reactivity literature. However, it should be noted that, even though we did not observe significantly stronger valence-related neural responses in the ACC, ventral striatum, OFC and PCC, we also did not observe significantly stronger craving-related responses in these areas. This might be due to a lack of statistical power.

Our findings have practical implications for the interpretation of previous studies, the design of future cue-reactivity research and for the further development of neuronal models of addiction. The amygdala has frequently been reported as activated in smoking cue-reactivity paradigms and has correctly been identified as an important region in addiction.^{23,40,41} However, previous studies did not disentangle which dimension the amygdala responds to. According to a literature search of the studies included in three cue-reactivity meta-analyses,^{18–20} only two out of 49 studies^{42,43}, that is, only 4% of the studies, accounted for stimulus valence in their study designs. Further, 80% of the included studies used a cue-reactivity block-design with the other studies using an event-related, yet non-parametric design. In neuroimaging, classical block designs are commonly used for because of their greater statistical power compared to, for example, parametric designs.^{32,44} However, when blocks of craving cues are contrasted with blocks of neutral images, the resulting brain activations reflect differences between these craving cues and neutral images along all functional dimensions of the stimuli and of nicotine dependence. Our results show that when the influence of valence is not accounted for in a cue-reactivity design, amygdala responses will most likely be driven by the valence and not the craving aspect of the presented smoking cues. This can be avoided by, for example, adjusting for valence during stimulus selection or specifically focusing on the craving dimension using a parametric modulator analysis approach. Publicly available smoking cue databases such as SmoCuDa (<https://smocuda.github.io/>³⁶) provide suitable stimuli for




FIGURE 4 Brain responses to the craving and valence ratings of the presented images. Group-level analyses revealed significant craving-related activation within the ACC, ventral striatum, and PCC and significant valence-related activation within the amygdala. We observed a significant difference between craving- and valence-related activation within the amygdala. Abbreviations: anterior cingulate cortex (ACC), orbitofrontal cortex (OFC) and posterior cingulate cortex (PCC)

implementing such designs. If this is not possible, the uncertainty regarding which smoking dimension is causing the activations should be kept in mind when interpreting them. These suggestions do not just apply to smoking research but can also inform other fields that work with fMRI-based cue reactivity paradigms, such as alcohol use disorder,⁴⁵ heroin use disorder,⁴⁶ cocaine use disorder,⁴⁷ obesity⁴⁸ and gambling disorder.⁴⁹

We applied a parametric fMRI design combined with behavioural craving and valence ratings to disentangle core components of craving- and valence-related brain regions. Such a specific parametric cue-reactivity approach can grant more detailed and precise insights into the complex dynamics of cue-driven craving in the brain, as it allows for focusing on separable stimulus dimension. Using this design, we identified key regions within the addiction network that were more sensitive to and more driven by either the craving or the emotional content of the presented smoking cues. Future studies might also investigate further stimulus dimensions which might be intertwined with craving-related results in key brain areas for addiction, such as salience or arousal. This can help to further specify the functional role of brain regions included in existing neuronal models of addiction.^{24,50,51} A better functional understanding and more precise mapping of the neural underpinnings of craving might also help to identify more reliable targets for clinical interventions, such as cue-exposure therapy or real-time fMRI neurofeedback. In particular, novel brain-based treatment approaches such as neurofeedback rely strongly on the correct selection of target brain areas and signals.⁵² Neurofeedback has been shown to be a promising tool for treating dysfunctional brain signals in substance use disorder,^{53,54} and in the field of tobacco use disorder, several brain areas have been successfully trained to reduce smoking cue-driven drug craving and to support smoking cessation.⁵⁵⁻⁵⁷

5 | CONCLUSION

Using a parametric cue-reactivity paradigm, we disentangled brain responses to craving and valence dimensions of smoking cues. Our findings suggest that the amygdala responds primarily to the valence component of such cues. This can refine the interpretation of previous reports of amygdala activity during smoking cue-reactivity and help designing future research aimed at teasing apart the many psychological dimensions that comprise nicotine dependence. Also, a more precise mapping of craving-related brain areas is an important step towards more tailored smoking cessation treatments.

ACKNOWLEDGEMENTS

The authors thank all volunteers for participating in this study. AH was supported by the Forschungskredit of the University of Zurich (FK-18-030). FS was supported by the Swiss National Science Foundation (BSSG10_155915, 100014_178841 and 32003B_166566), the Foundation for Research in Science and the Humanities at the

University of Zurich (STWF-17-012) and the Baugarten Stiftung. AM was supported by the Swiss National Science Foundation (P2SKP3_178107). MK was supported by the National Bank Fellowship Award (Montreal Neurological Institute, McGill University, Canada). Open Access Funding provided by Universitat Zurich.

CONFLICT OF INTEREST

No support by the industry was received. All authors declare no conflict of interest.

ETHICS STATEMENT

This study was conducted in accordance with the Declaration of Helsinki and was approved by the local ethics committee (University of Zurich).

AUTHORS CONTRIBUTIONS

AH, AM, RS, LMH, MK, ABB, BBQ, MH and FS were responsible for the conceptualization of the project. AH and AM were responsible for data curation. AH was responsible for the formal analysis. AH, AM, RS, MK, BBQ, MH and FS were responsible for the methodology. RS provided software. LMH, ABB, ES, MH and FS provided resources. FS was provided funding and supervision. AH, AM and FS created a first draft of the manuscript. All authors critically reviewed the content of the manuscript and approved the final version for publication.

DATA AVAILABILITY STATEMENT

Code and data availability The used smoking stimuli, a more detailed overview of stimuli ratings, and the exact scripts used for performing stimulus ratings are all available on the Open Science Framework (OSF) platform (<https://osf.io/6gwy5/>). Further, we have made all scripts used for fMRI analyses and image presentation publicly available in another repository on the OSF platform (<https://osf.io/6y8fu/>). This repository also includes group-level neuroimaging data, while individual data were not allowed to be shared publicly by our local ethics regulations.

ORCID

Amelie Haug  <https://orcid.org/0000-0002-9583-6585>

Boris B. Quednow  <https://orcid.org/0000-0001-7933-2865>

REFERENCES

1. World Health Organization. *WHO Report on the Global Tobacco Epidemic*. 2017.
2. Samet JM. Tobacco smoking. The leading cause of preventable disease worldwide. *Thorac Surg Clin*. 2013;23(2):103-112. <https://doi.org/10.1016/j.thorsurg.2013.01.009>
3. Thyrian JR, Panagiotakos DB, Polychronopoulos E, West R, Zatonski W, John U. The relationship between smokers' motivation to quit and intensity of tobacco control at the population level: a comparison of five European countries. *BMC Public Health*. 2008;8(1):1-6. <https://doi.org/10.1186/1471-2458-8-2>
4. Piasecki TM. Relapse to smoking. *Clin Psychol Rev*. 2006;26(2):196-215. <https://doi.org/10.1016/j.cpr.2005.11.007>

5. Quednow BB, Herdener M. Human pharmacology for addiction medicine: from evidence to clinical recommendations. In: *Progress in Brain Research*. Vol 224. 1st ed. Elsevier B.V.; 2016:227-250. <https://doi.org/10.1016/bs.pbr.2015.07.017>
6. Cohen S, Lichtenstein E. Perceived stress, quitting smoking, and smoking relapse. *Health Psychol*. 1990;9(4):466-478. <https://doi.org/10.1037/0278-6133.9.4.466>
7. Doran N, Spring B, McChargue D, Pergadia M, Richmond M. Impulsivity and smoking relapse. *Nicotine Tob Res*. 2004;6(4):641-647. <https://doi.org/10.1080/14622200410001727939>
8. Gulliver SB, Hughes JR, Solomon LJ, Dey AN. An investigation of self-efficacy, partner support and daily stresses as predictors of relapse to smoking in self-quitters. *Addiction*. 1995;90(6):767-772. <https://doi.org/10.1046/j.1360-0443.1995.9067673.x>
9. Bagot KS, Heishman SJ, Moolchan ET. Tobacco craving predicts lapse to smoking among adolescent smokers in cessation treatment. *Nicotine Tob Res*. 2007;9(6):647-652. <https://doi.org/10.1080/14622200701365178>
10. Elwafi HM, Witkiewitz K, Mallik S, IV TAT, Brewer JA. Mindfulness training for smoking cessation: moderation of the relationship between craving and cigarette use. *Drug Alcohol Depend*. 2013;130(1-3):222-229. <https://doi.org/10.1016/j.drugalcdep.2012.11.015>
11. Russell MA. Nicotine replacement: the role of blood nicotine levels, their rate of change, and nicotine tolerance. *Prog Clin Biol Res*. 1988;261:63-94.
12. Sayette MA, Shiffman S, Tiffany ST, Niaura RS, Martin CS, Schadel WG. The measurement of drug craving. *Addiction*. 2000;95(8):189-210. <https://doi.org/10.1080/09652140050111762>
13. Gilbert HM, Warburton DM. Craving: a problematic concept in smoking research. *Addict Res Theory*. 2000;8(4):381-397. <https://doi.org/10.3109/1606635000909522>
14. Shiffman S, Engberg JB, Paty JA, et al. A day at a time: predicting smoking lapse from daily urge. *J Abnorm Psychol*. 1997;106(1):104-116. <https://doi.org/10.1037/0021-843X.106.1.104>
15. Hughes JR. Tobacco withdrawal in self-quitters. *J Consult Clin Psychol*. 1992;60(5):689-697. <https://doi.org/10.1037/0022-006x.60.5.689>
16. Tiffany ST, Drobes DJ. The development and initial validation of a questionnaire on smoking urges. *Br J Addict*. 1991;86(11):1467-1476. <https://doi.org/10.1111/j.1360-0443.1991.tb01732.x>
17. Ferguson SG, Shiffman S. The relevance and treatment of cue-induced cravings in tobacco dependence. *J Subst Abuse Treat*. 2009;36(3):235-243. <https://doi.org/10.1016/j.jsat.2008.06.005>
18. Niaura R, Shadel WG, Abrams DB, Monti PM, Rohsenow DJ, Sirota A. Individual differences in cue reactivity among smokers trying to quit: effects of gender and cue type. *Addict Behav*. 1998;23(2):209-224. [https://doi.org/10.1016/S0306-4603\(97\)00043-9](https://doi.org/10.1016/S0306-4603(97)00043-9)
19. Chase HW, Eickhoff SB, Laird AR, Hogarth L. The neural basis of drug stimulus processing and craving: an activation likelihood estimation meta-analysis. *Biol Psychiatry*. 2011;70(8):785-793. <https://doi.org/10.1016/j.biopsych.2011.05.025>
20. Kühn S, Gallinat J. Common biology of craving across legal and illegal drugs—a quantitative meta-analysis of cue-reactivity brain response. *Eur J Neurosci*. 2011;33(7):1318-1326. <https://doi.org/10.1111/j.1460-9568.2010.07590.x>
21. Tang DW, Fellows LK, Small DM, Dagher A. Food and drug cues activate similar brain regions: a meta-analysis of functional MRI studies. *Physiol Behav*. 2012;106(3):317-324. <https://doi.org/10.1016/j.physbeh.2012.03.009>
22. Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. *Lancet Psychiatry*. 2016;3(8):760-773. [https://doi.org/10.1016/S2215-0366\(16\)00104-8](https://doi.org/10.1016/S2215-0366(16)00104-8)
23. Schultz W, Apicella P, Scarnati E, Ljungberg T. Neuronal activity in monkey ventral striatum related to the expectation of reward. *J Neurosci*. 1992;12(12):4595-4610. <https://doi.org/10.1523/jneurosci.12-12-04595.1992>
24. Gallagher M, Chiba AA. The amygdala and emotion. *Curr Opin Neurobiol*. 1996;6(2):221-227. [https://doi.org/10.1016/S0959-4388\(96\)80076-6](https://doi.org/10.1016/S0959-4388(96)80076-6)
25. See RE, Fuchs RA, Ledford CC, McLaughlin J. Drug addiction, relapse, and the amygdala. *Ann N Y Acad Sci*. 2003;985:294-307.
26. Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. *Am J Psychiatry*. 2005;162(8):1403-1413. <https://doi.org/10.1176/appi.ajp.162.8.1403>
27. Schoenbaum G, Roesch MR, Stalnaker TA. Orbitofrontal cortex, decision-making and drug addiction. *Trends Neurosci*. 2006;29(2):116-124. <https://doi.org/10.1016/j.tins.2005.12.006>
28. Brody AL, Mandelkern MA, Olmstead RE, et al. Neural substrates of resisting craving during cigarette cue exposure. *Biol Psychiatry*. 2007;62(6):642-651. <https://doi.org/10.1016/j.biopsych.2006.10.026>
29. Janes AC, Pizzagalli DA, Richardt S, et al. Brain reactivity to smoking cues prior to smoking cessation predicts ability to maintain tobacco abstinence. *Biol Psychiatry*. 2010;67(8):722-729. <https://doi.org/10.1016/j.biopsych.2009.12.034>
30. Allenby C, Falcone M, Wileyto EP, et al. Neural cue reactivity during acute abstinence predicts short-term smoking relapse. *Addict Biol*. 2020;25(2):1-9. <https://doi.org/10.1111/adb.12733>
31. Costafreda SG, Brammer MJ, David AS, Fu CHY. Predictors of amygdala activation during the processing of emotional stimuli: a meta-analysis of 385 PET and fMRI studies. *Brain Res Rev*. 2008;58(1):57-70. <https://doi.org/10.1016/j.brainresrev.2007.10.012>
32. Liu TT, Frank LR, Wong EC, Buxton RB. Detection power, estimation efficiency, and predictability in event-related fMRI. *Neuroimage*. 2001;13(4):759-773. <https://doi.org/10.1006/nimg.2000.0728>
33. Quednow BB, Kühn KU, Hoenig K, Maier W, Wagner M. Prepulse inhibition and habituation of acoustic startle response in male MDMA ('Ecstasy') users, cannabis users, and healthy controls. *Neuropsychopharmacology*. 2004;29(5):982-990. <https://doi.org/10.1038/sj.npp.1300396>
34. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom K-O. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. *Br J Addict*. 1991;86(9):1119-1127. <https://ai2-s2-pdfs.s3.amazonaws.com/74c8/dd44c488807e054a5ed8711f6bc7b2fbfeaea.pdf>
35. Cox S, Stephen T, Tiffany L. Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings. *Nicotine Tob Res*. 2001;3(1):7-16. <https://doi.org/10.1080/14622200124218>
36. Manoliu A, Haugg A, Sladky R, et al. SmoCuDa: a validated smoking cue database to reliably induce craving in tobacco use disorder. *Eur Addict Res*. 2020;27(2):107-114. <https://doi.org/10.1159/000509758>
37. Lang PJ, Bradley MM, Cuthbert BN. International Affective Picture System (IAPS): technical manual and affective ratings. *NIMH Cent Study Emot Atten*. 1997;1:39-58.
38. Gilbert DG, Rabinovich NE. International Smoking Image Series, Version 1. 2.; 1999.
39. Wilson SJ, Sayette MA, Fiez JA. Prefrontal responses to drug cues: A neurocognitive analysis. *Nat Neurosci*. 2004;7(3):211-214. <https://doi.org/10.1038/nn1200>
40. Everitt BJ, Parkinson JA, Olmstead MC, Arroyo M, Robbins P, Robbins TW. Associative processes in addiction and reward. The role of amygdala-ventral striatal subsystems. *Ann N Y Acad Sci*. 1999;877(1 ADVANCING FRO):412-438. <https://doi.org/10.1111/j.1749-6632.1999.tb09280.x>
41. Roberts AJ, Koob GF. The neurobiology of addiction. *Alcohol Heal Res World*. 1997;21(2):101-106.
42. Filbey FM, Claus E, Audette AR, et al. Exposure to the taste of alcohol elicits activation of the mesocorticolimbic neurocircuitry. *Neuropsychopharmacology*. 2008;33(6):1391-1401. <https://doi.org/10.1038/sj.npp.1301513>

43. Franklin T, Wang Z, Suh JJ, et al. Effects of varenicline on smoking cue-triggered neural and craving responses. *Arch Gen Psychiatry*. 2011;68(5):516-526. <https://doi.org/10.1001/archgenpsychiatry.2010.190>
44. Miezin FM, Maccotta L, Ollinger JM, Petersen SE, Buckner RL. Characterizing the hemodynamic response: effects of presentation rate, sampling procedure, and the possibility of ordering brain activity based on relative timing. *Neuroimage*. 2000;11(6 Pt 1):735-759. <https://doi.org/10.1006/nimg.2000.0568>
45. Schacht JP, Anton RF, Myrick H. Functional neuroimaging studies of alcohol cue reactivity: a quantitative meta-analysis and systematic review. *Addict Biol*. 2013;18(1):121-133. <https://doi.org/10.1111/j.1369-1600.2012.00464.x>
46. Yang Z, Xie J, Shao YC, et al. Dynamic neural responses to cue-reactivity paradigms in heroin-dependent users: an fMRI study. *Hum Brain Mapp*. 2009;30(3):766-775. <https://doi.org/10.1002/hbm.20542>
47. Wilcox CE, Teshiba TM, Merideth F, Ling J, Mayer AR. Enhanced cue reactivity and fronto-striatal functional connectivity in cocaine use disorders. *Drug Alcohol Depend*. 2011;115(1-2):137-144. <https://doi.org/10.1016/j.drugalcdep.2011.01.009>
48. Boswell RG, Kober H. Food cue reactivity and craving predict eating and weight gain: a meta-analytic review. *Obes Rev*. 2016;17(2):159-177. <https://doi.org/10.1111/obr.12354>
49. Limbrick-Oldfield EH, Mick I, Cocks RE, et al. Neural substrates of cue reactivity and craving in gambling disorder. *Transl Psychiatry*. 2017;7(1):1-10. <https://doi.org/10.1038/tp.2016.256>
50. Berridge KC, Robinson TE. Liking, wanting and the incentive-sensitization theory. *Am Psychol*. 2016;71(8):670-679. <https://doi.org/10.1037/amp0000059>. Liking
51. Volkow ND, Koob GF, McLellan AT. Neurobiologic advances from the brain disease model of addiction. *N Engl J Med*. 2016;374(4):363-371. <https://doi.org/10.1056/NEJMr1511480>
52. Sitaram R, Ros T, Stoeckel LE, et al. Closed-loop brain training: the science of neurofeedback. *Nat Neurosci*. 2016;18(2):86-100. <https://doi.org/10.1038/nrn.2016.164>
53. Kirschner M, Sladky R, Haugg A, et al. Self-regulation of the dopaminergic reward circuit in cocaine users with mental imagery and neurofeedback. *EBioMedicine*. 2018;37:489-498. <https://doi.org/10.1016/j.ebiom.2018.10.052>
54. Karch S, Keeser D, Hümmer S, et al. Modulation of craving related brain responses using real-time fMRI in patients with alcohol use disorder. *PLoS One*. 2015;10(7):e0133034. <https://doi.org/10.1371/journal.pone.0133034>
55. Hartwell KJ, Hanlon CA, Li X, et al. Individualized real-time fMRI neurofeedback to attenuate craving in nicotine-dependent smokers. *J Psychiatry Neurosci*. 2016;41(1):48-55. <https://doi.org/10.1503/jpn.140200>
56. Kim D-Y, Yoo S-S, Tegethoff M, Meinschmidt G, Lee J-H. The inclusion of functional connectivity information into fMRI-based neurofeedback improves its efficacy in the reduction of cigarette cravings. *J Cogn Neurosci*. 2015;27(8):1552-1572. <https://doi.org/10.1162/jocn>
57. Karch S, Paolini M, Gschwendtner S, et al. Real-time fMRI neurofeedback in patients with tobacco use disorder during smoking cessation: functional differences and implications of the first training session in regard to future abstinence or relapse. *Front Hum Neurosci*. 2019;13(March):1-17. <https://doi.org/10.3389/fnhum.2019.00065>

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of this article.

How to cite this article: Haugg A, Manoliu A, Sladky R, et al. Disentangling craving- and valence-related brain responses to smoking cues in individuals with nicotine use disorder. *Addiction Biology*. 2022;27(1):e13083. doi:10.1111/adb.13083